Traders Purchase High Volume of Call Options on Bioventus (NASDAQ:BVS)

Bioventus Inc. (NASDAQ:BVS) was the target of unusually large options trading on Monday. Stock traders bought 10,317 call options on the stock. This represents an increase of 5,933% compared to the average daily volume of 171 call options.

Bioventus Stock Up 13.3%

Shares of NASDAQ:BVS traded up $1.39 during trading hours on Monday, reaching $11.87. The stock had a trading volume of 501,946 shares, compared to its average volume of 467,663. Bioventus has a 1 year low of $5.81 and a 1 year high of $11.93. The firm’s 50 day moving average is $9.53 and its 200-day moving average is $8.84. The company has a debt-to-equity ratio of 1.08, a quick ratio of 1.13 and a current ratio of 1.69. The stock has a market capitalization of $991.62 million, a price-to-earnings ratio of 28.95, a P/E/G ratio of 1.35 and a beta of 0.65.

Bioventus (NASDAQ:BVS) last released its quarterly earnings data on Wednesday, May 6th. The company reported $0.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.09 by $0.06. The business had revenue of $132.09 million during the quarter. Bioventus had a net margin of 4.94% and a return on equity of 29.97%. Bioventus has set its FY 2026 guidance at 0.750-0.790 EPS. Research analysts predict that Bioventus will post 0.77 earnings per share for the current fiscal year.

Institutional Trading of Bioventus

A number of institutional investors have recently bought and sold shares of BVS. Marshall Wace LLP boosted its position in shares of Bioventus by 0.4% during the 4th quarter. Marshall Wace LLP now owns 288,900 shares of the company’s stock worth $2,149,000 after acquiring an additional 1,281 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of Bioventus by 7.2% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,048 shares of the company’s stock worth $211,000 after acquiring an additional 1,538 shares in the last quarter. Mercer Global Advisors Inc. ADV raised its position in shares of Bioventus by 16.2% during the 4th quarter. Mercer Global Advisors Inc. ADV now owns 13,529 shares of the company’s stock worth $101,000 after acquiring an additional 1,887 shares in the last quarter. Deutsche Bank AG lifted its stake in Bioventus by 8.2% during the fourth quarter. Deutsche Bank AG now owns 25,138 shares of the company’s stock worth $187,000 after purchasing an additional 1,908 shares during the last quarter. Finally, Engineers Gate Manager LP lifted its stake in Bioventus by 6.0% during the fourth quarter. Engineers Gate Manager LP now owns 68,889 shares of the company’s stock worth $513,000 after purchasing an additional 3,909 shares during the last quarter. 62.94% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

BVS has been the topic of several research analyst reports. Weiss Ratings reiterated a “hold (c)” rating on shares of Bioventus in a report on Tuesday, June 2nd. CJS Securities started coverage on Bioventus in a report on Friday, March 27th. They set a “market outperform” rating and a $14.00 target price for the company. Barrington Research reaffirmed an “outperform” rating and issued a $14.00 target price on shares of Bioventus in a research report on Tuesday, June 30th. Finally, Canaccord Genuity Group reiterated a “buy” rating and set a $15.00 price target on shares of Bioventus in a research note on Tuesday, June 16th. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Buy” and an average price target of $14.20.

Bioventus Company Profile

Bioventus, headquartered in Durham, North Carolina, is a global medical device company specializing in orthobiologic solutions aimed at accelerating healing and improving patient outcomes in musculoskeletal conditions. The company develops and commercializes a portfolio of non?surgical therapies designed to address bone healing, osteoarthritis pain management and soft tissue repair. Its flagship EXOGEN® Ultrasound Bone Healing System utilizes low?intensity pulsed ultrasound technology to stimulate bone growth and has been widely used in the management of delayed fractures and nonunions.